{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:58:26Z","timestamp":1773961106842,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ecl.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:16:09Z","timestamp":1621448169000},"page":"205-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis"],"prefix":"10.1016","volume":"50","author":[{"given":"Meltem","family":"Zeytinoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra C.","family":"Naaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura T.","family":"Dickens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2021.03.004_bib1","series-title":"Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005\u20132010","author":"Looker","year":"2015"},{"issue":"11","key":"10.1016\/j.ecl.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.ecl.2021.03.004_bib3","series-title":"Milliman Research Report: Medicare cost of osteoporotic fractures. The Clinical and Cost Burden of an Important Consequence of Osteoporosis","first-page":"14","author":"Hansen","year":"2019"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.004_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/jc.2007-0646","article-title":"The role of receptor activator of nuclear factor-\u03baB (RANK)\/RANK ligand\/osteoprotegerin: clinical implications","volume":"92","author":"Vega","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.004_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.004_bib11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"30","key":"10.1016\/j.ecl.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.004_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ecl.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.004_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"s1","key":"10.1016\/j.ecl.2021.03.004_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.ecl.2021.03.004_bib21","first-page":"1953","volume":"25","author":"Brown","year":"2014","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.ecl.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.004_bib24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2021.03.004_bib25","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.004_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcified Tissue Int"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.004_bib29","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.ecl.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.004_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.004_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.ecl.2021.03.004_bib33","doi-asserted-by":"crossref","first-page":"100267","DOI":"10.1016\/j.bonr.2020.100267","article-title":"Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation","volume":"12","author":"Anastasilakis","year":"2020","journal-title":"Bone Rep"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11657-019-0676-0","article-title":"Second rebound-associated vertebral fractures after denosumab discontinuation","volume":"15","author":"Niimi","year":"2020","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ecl.2021.03.004_bib35","doi-asserted-by":"crossref","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","volume":"179","author":"Gonzalez-Rodriguez","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.ecl.2021.03.004_bib37","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.004_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CP203361","article-title":"Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate","volume":"57","author":"Bandeira","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","article-title":"Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates","volume":"103","author":"Tripto-Shkolnik","year":"2018","journal-title":"Calcified Tissue Int"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.004_bib40","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2021.03.004_bib41","first-page":"5432751","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.ecl.2021.03.004_bib42","unstructured":"Ebina K, Miyama A, Hirao M, et al. Assessment of the effects of sequential treatment after discontinuing denosumab in 64 patients with postmenopausal osteoporosis. Abstract presented at: American Society of Bone and Mineral Research, Orlando, FL, 2019."},{"issue":"9886","key":"10.1016\/j.ecl.2021.03.004_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"9999","key":"10.1016\/j.ecl.2021.03.004_bib44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2021.03.004_bib45","doi-asserted-by":"crossref","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","article-title":"Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report","volume":"13","author":"Kashii","year":"2020","journal-title":"Bone Rep"},{"issue":"3","key":"10.1016\/j.ecl.2021.03.004_bib46","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2021.03.004_bib47","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.004_bib48","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.ecl.2021.03.004_bib49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcified Tissue Int"},{"key":"10.1016\/j.ecl.2021.03.004_bib50","unstructured":"Dickens L, Vokes T. Oral vs intravenous bisphosphonates for preventing bone loss after denosumab discontinuation. Abstract presented at: American Society of Bone and Mineral Research, Orlando, FL, 2019."},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcified Tissue Int"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","article-title":"Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up","volume":"105","author":"Horne","year":"2019","journal-title":"Calcified Tissue Int"},{"key":"10.1016\/j.ecl.2021.03.004_bib53","unstructured":"Popp A, Bock O, Senn C, et al. Early recurrence of increased bone turnover markers after initial response to single dose zoledronate following denosumab discontinuation in postmenopausal women. Abstract presented at: American Society of Bone and Mineral Research, Orlando, FL, 2019."},{"issue":"7","key":"10.1016\/j.ecl.2021.03.004_bib54","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A\u00a0single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.004_bib55","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.ecl.2021.03.004_bib56","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"24","key":"10.1016\/j.ecl.2021.03.004_bib57","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2021.03.004_bib58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"1","key":"10.1016\/j.ecl.2021.03.004_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J\u00a0Bone Mineral Res"},{"issue":"12","key":"10.1016\/j.ecl.2021.03.004_bib61","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00198-020-05569-9","article-title":"Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts","volume":"31","author":"Thomas","year":"2020","journal-title":"Osteoporos Int"},{"issue":"s4","key":"10.1016\/j.ecl.2021.03.004_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142016","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.03.004_bib63","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.03.004_bib64","article-title":"Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension","author":"Ramchand","year":"2021","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.ecl.2021.03.004_bib65","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Reports"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:01Z","timestamp":1760175961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0889852921000165"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.004","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}